Full-Time

Scientist – Hybrid Computational / Synthetic Biology

Confirmed live in the last 24 hours

Manifold Bio

Manifold Bio

11-50 employees

Designs precision biologics using in vivo methods

Biotechnology
Healthcare

Senior

Boston, MA, USA

Hybrid position requiring both wet and dry lab experience.

Category
Bioinformatics
Computational Biology
Biology & Biotech
Required Skills
Python
Jupyter
Git
AWS
Requirements
  • PhD or equivalent experience in protein and or molecular biology, biological engineering or a related field; must total 5+ years hands-on molecular biology wet lab experience and/or NGS data analysis experience
  • Experience going end-to-end from experimental design through cloning, execution, NGS, and analysis
  • Expertise in statistical computing and willingness to adapt our python / jupyter / git / AWS stack
  • Collaborative, curious, flexible, and strong communication skills
Responsibilities
  • Design, execute, interpret and iterate on novel library-based experiments
  • Apply statistical methods and machine learning to NGS data to identify novel variants
  • Provide deepful insightful analyses of team’s NGS experiments and advise on next steps
  • Develop novel protein engineering platform technologies

Manifold Bio focuses on creating precision biologics for the pharmaceutical industry. Their main product is an in vivo drug design platform, which allows for drug testing within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment. This capability is especially beneficial for testing complex biologics, which are large molecule drugs derived from living organisms. Manifold Bio stands out from competitors by being the first to offer this in vivo drug design approach. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to develop new therapeutics.

Company Stage

Series A

Total Funding

$58.8M

Headquarters

Boston, Massachusetts

Founded

2020

Growth & Insights
Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

33%
Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $40M in Series A funding, indicating strong market interest.
  • Major investors like Tencent and Horizons Ventures show confidence in their innovation.
  • Their technology addresses the in vivo testing bottleneck in drug development.

What critics are saying

  • Emerging competition in protein barcoding could threaten their market position.
  • Rapid AI advancements may outpace their current platform capabilities.
  • Regulatory challenges could delay multiplexed in vivo testing approvals.

What makes Manifold Bio unique

  • Manifold Bio's mCodes™ technology enables multiplexed protein analysis in vivo.
  • Their platform allows simultaneous testing of multiple molecules in living systems.
  • They are pioneering in vivo biologics design, a first in the pharmaceutical industry.

Help us improve and share your feedback! Did you find this helpful?